allopurinol and Galactosemias

allopurinol has been researched along with Galactosemias* in 3 studies

Reviews

1 review(s) available for allopurinol and Galactosemias

Article	Year
Inborn errors as causes of acute disease in infancy. Seminars in perinatology, 1991, Volume: 15, Issue:1 Suppl 1 Topics: Acidosis, Lactic; Acute Disease; Ammonia; Galactosemias; Humans; Hyperglycemia; Infant; Infant, Newborn; Metabolism, Inborn Errors; Microbodies; Xanthine Oxidase	1991

Other Studies

2 other study(ies) available for allopurinol and Galactosemias

Article	Year
Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis. Biochemical and biophysical research communications, 1990, May-16, Volume: 168, Issue:3 Rats fed a high galactose (30% galactose) diet (w/w) or made diabetic by injecting streptozotocin developed mature cataracts in approximately 45 and 90 days, respectively. Addition of allopurinol, a commonly used drug in the therapy of gout, to the high galactose diet or to the normal diet fed to diabetic rats advanced cataractogenesis in both the groups by approximately 50%. Allopurinol fed to control rats did not cause cataract formation. Feeding butylated hydroxy toluene (BHT), an antioxidant, prevented the allopurinol-induced advancement of cataract formation in galactosemic and diabetic rats. Assuming that these results are applicable in human subjects, there is need for caution in using allopurinol for the therapy of gout in diabetic subjects. Topics: Allopurinol; Animals; Butylated Hydroxytoluene; Cataract; Diabetes Mellitus, Experimental; Diet; Galactose; Galactosemias; Lipid Peroxidation; Male; Rats; Rats, Inbred Strains	1990
Allopurinol kinetics in humans as a means to assess liver function: evaluation of an allopurinol loading test. Scandinavian journal of clinical and laboratory investigation, 1988, Volume: 48, Issue:1 A newly developed liver function test was performed on 18 apparently healthy individuals and 29 patients with liver disease. After intravenous injection of a low dose allopurinol (17.1 mumol/kg body mass), blood specimens were collected during 1 h. Plasma analyses of allopurinol and its metabolite oxipurinol were performed and the data were processed by means of a computer-based biodynamic model. This modelling approach makes it possible to estimate parameters, containing information about liver perfusion, hepatocyte membrane transport and hepatocyte cell mass. One parameter (kA31) showed complete discrimination between the reference sample group of healthy individuals and patients with severe liver dysfunction. In a reference sample group of patients with slightly to moderately reduced liver function, only a few patients (5/20) had a kA31 value over the decision limit. In this respect, the allopurinol loading test is superior to the conventional intravenous galactose tolerance test. Topics: Adolescent; Adult; Aged; Allopurinol; Evaluation Studies as Topic; Female; Galactosemias; Humans; Injections, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Oxypurinol; Time Factors	1988

Article

Year

Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis.

Biochemical and biophysical research communications, 1990, May-16, Volume: 168, Issue:3

Rats fed a high galactose (30% galactose) diet (w/w) or made diabetic by injecting streptozotocin developed mature cataracts in approximately 45 and 90 days, respectively. Addition of allopurinol, a commonly used drug in the therapy of gout, to the high galactose diet or to the normal diet fed to diabetic rats advanced cataractogenesis in both the groups by approximately 50%. Allopurinol fed to control rats did not cause cataract formation. Feeding butylated hydroxy toluene (BHT), an antioxidant, prevented the allopurinol-induced advancement of cataract formation in galactosemic and diabetic rats. Assuming that these results are applicable in human subjects, there is need for caution in using allopurinol for the therapy of gout in diabetic subjects.

Topics: Allopurinol; Animals; Butylated Hydroxytoluene; Cataract; Diabetes Mellitus, Experimental; Diet; Galactose; Galactosemias; Lipid Peroxidation; Male; Rats; Rats, Inbred Strains

1990

Allopurinol kinetics in humans as a means to assess liver function: evaluation of an allopurinol loading test.

Scandinavian journal of clinical and laboratory investigation, 1988, Volume: 48, Issue:1

A newly developed liver function test was performed on 18 apparently healthy individuals and 29 patients with liver disease. After intravenous injection of a low dose allopurinol (17.1 mumol/kg body mass), blood specimens were collected during 1 h. Plasma analyses of allopurinol and its metabolite oxipurinol were performed and the data were processed by means of a computer-based biodynamic model. This modelling approach makes it possible to estimate parameters, containing information about liver perfusion, hepatocyte membrane transport and hepatocyte cell mass. One parameter (kA31) showed complete discrimination between the reference sample group of healthy individuals and patients with severe liver dysfunction. In a reference sample group of patients with slightly to moderately reduced liver function, only a few patients (5/20) had a kA31 value over the decision limit. In this respect, the allopurinol loading test is superior to the conventional intravenous galactose tolerance test.

Topics: Adolescent; Adult; Aged; Allopurinol; Evaluation Studies as Topic; Female; Galactosemias; Humans; Injections, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Oxypurinol; Time Factors

1988